Wael Muakkassa
Urology · Oneida, NYNPI 1447364609
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,438 and has fallen 92.5% since, to $108 in 2023.
Across 201 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$704
- Neotract Inc.$692
- Teleflex LLC$333
- Dendreon Pharmaceuticals LLC$304
- Medtronic$290
- Urovant Sciences Inc$219
- plus $2K from 25 others
Across 7 payments — averaging $28,029 each. An ownership or investment interest held by the physician or an immediate family member.
- Applied Medical Corporation$196K
What the payments were for
- Travel & lodging$1463%
- Food & beverage$4,37693%
- Education$1704%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 31 | $704 |
| Neotract Inc. | 13 | $692 |
| Teleflex LLC | 5 | $333 |
| Dendreon Pharmaceuticals LLC | 16 | $304 |
| Medtronic(2 entities) | 11 | $290 |
| Urovant Sciences Inc | 11 | $219 |
| AbbVie(2 entities) | 13 | $209 |
| Coloplast | 10 | $207 |
| Pfizer | 14 | $197 |
| Tolmar Pharmaceuticals, Inc. | 8 | $176 |
| Johnson & Johnson | 10 | $174 |
| Myriad Genetic Laboratories, Inc. | 8 | $136 |
| Antares Pharma, Inc. | 6 | $135 |
| Boston Scientific | 4 | $124 |
| Urogen Pharma, Inc. | 5 | $114 |
| Bayer | 6 | $108 |
| Endo Pharmaceuticals Inc. | 7 | $106 |
| Axonics, Inc. | 4 | $106 |
| 180 Medical, Inc. | 3 | $59 |
| Blue Earth Diagnostics | 2 | $47 |
| Bard Access Systems, Inc. | 1 | $40 |
| Telix Pharmaceuticals | 2 | $38 |
| Olympus America Inc. | 1 | $27 |
| Clarus Therapeutics Inc. | 2 | $25 |
| Ferring Pharmaceuticals Inc. | 2 | $24 |
| Merck | 1 | $20 |
| Myovant Sciences Inc. | 1 | $18 |
| Smith+Nephew | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$383
- UroLift System$126
- INTERSTIM$111
How this compares
$4,691 in reported general payments places this provider in the 65th percentile of 952 urology providers in New York.
Other urology in Oneida
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Evan GoldfischerPoughkeepsie$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.